Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities

Pharmaceutical Research

Volumn 15, Issue 1, 1998, Pages 47-52

  Polli, James E ^a   Ginski, Mark J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Caco 2 cells; Human; Oral absorption; Permeability; Pharmacokinetics

Indexed keywords

METOPROLOL TARTRATE; PIROXICAM; RANITIDINE;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DISSOLUTION; DRUG ABSORPTION; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PENETRATION; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; MEMBRANE PERMEABILITY; MONOLAYER CULTURE; PRIORITY JOURNAL; TABLET; TECHNIQUE; THEORY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ANTIHYPERTENSIVE AGENTS; CACO-2 CELLS; HUMANS; INTESTINAL ABSORPTION; METOPROLOL; MODELS, BIOLOGICAL; PERMEABILITY; PIROXICAM; RANITIDINE;

EID: 0031938959     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011992518592     Document Type: Article

References (27)

1. J. E. Polli, G. S. Rekhi, L. L. Augsburger, and V. P. Shah. J. Pharm. Sci. 86:690-700 (1997).
2. R. T. Borchardt, P. L. Smith, and G. Wilson. Models for Assessing Drug Absorption and Metabolism, Plenum Press, New York, 1996.
3. I. J. Hildalgo, T. J. Raub, and R. T. Borchardt. Gastroenterology 96:736-749 (1989).
4. W. Rubas, N. Jezyk, and G. M. Grass. Pharm. Res. 10:113-118 (1993).
5. M. Hu, L. Zheng, J. Chen, L. Liu, Y. Zhu, A. H. Dantzig, and R. E. Stratford. Pharm. Res. 12:1120-1125 (1995).
6. P. Artursson and J. Karlsson. Biochem. Biophys. Res. Commun. 175:880-885 (1991).
7. R. E. Notari, J. L. DeYoung, and R. H. Reuning. J. Pharm. Sci. 61:135-138 (1972).
8. D. Perrier and M. Gibaldi. J. Pharm. Sci. 62:225-228 (1972).
9. J. E. Polli, J. R. Crison, and G. L. Amidon. J. Pharm. Sci. 85:753-760 (1996).
10. L. J. Leeson and H. Weintraub. J. Pharm. Sci. 62:1936-1941 (1972).
11. D. A. Piscitelli, J. McGlone Dalby, C. Propst, S. Goskonda, P. Schwartz, L. J. S. Goskonda, C. Propst, L. Augsburger, P. Schwartz, and L. Lesko. Pharm. Res. 11:S-163 (1994).
12. D. A. Piscitelli, J. McGlone Dalby, L. Augsburger, V. P. Shah, L. J. Lesko, and D. Young. Pharm. Res. 12:S-417 (1995).
13. D. A. Piscitelli, J. McGlone Dalby, C. Propst, S. Goskonda, P. Schwartz, L. J. Lesko, V. Shah, D. Young, and L. L. Augsburger. To be submitted to Pharm. Dev. Technol.
14. D. A. Piscitelli, S. Bigora, C. Propst, S. Goskonda, P. Schwartz, L. J. Lesko, L. L. Augsburger, and D. Young. Pharm. Dev. Technol. (in press).
15. G. S. Rekhi, N. E. Eddington, M. J. Fossler, P. Schwartz, L. J. Lesko, and L. L. Augsburger. Pharm. Dev. Technol. 2:11-24 (1997).
16. S. M. Grant, H. D. Langtry, and R. N. Brogden. Drugs 37:801-870 (1989).
17. S. S. Davis, J. G. Hardy, and J. W. Fara. Gut 27:886-892 (1986).
18. K. T. Olkkola, A. V. Brunetto, and M. J. Mattila. Clin Pharmacokinet. 26:107-120 (1994).
19. U. Fagerholm, M. Johansson, and H. Lennernas. Pharm. Res. 13:1336-1342 (1996).
20. D. Fleisher. Gastrointestinal Transport of Peptides: Experimental Systems. In M. D. Taylor and G. L. Amidon (eds.), Peptide-based Drug Design: Controlling Transport and Metabolism, American Chemical Society, Washington, DC, 1995, pp. 501-523.
21. The International Commission on Radiological Protection, Report on the Task Group on Reference Man, Pergamon Press, Oxford, 1974.
22. J. B. Dressman, G. L. Amidon, and D. Fleisher. J. Pharm. Sci. 74:588-589 (1985).
23. L. S. Gan, P. H. Hsyu, J. F. Pritchard, and D. Thakker. Pharm. Res. 10:1722-1725 (1993).
24. P. Artursson, A. Ungell, and J. Lofroth. Pharm. Res. 10:1123-1129 (1993).
25. A. Collett, E. Sims, D. Walker, Y. L. He, J. Ayrton, M. Rowland, and G. Warhurst. Pharm. Res. 13:216-221 (1996).
26. S. E. Crowe and M. H. Purdue. Gastroenterology 105:764-772 (1993).
27. H. Lennernas, L. Knutson, T. Knutson, L. Lesko, T. Salmonson, and G. L. Amidon. Pharm. Res. 12:S-295 (1995).